135 related articles for article (PubMed ID: 17988579)
1. [Study of the immunological mechanism of anti-tumor effects of 5-FU by establishing EL4 tumor-bearing mouse models].
Li ML; Li CG; Shu XH; Li MX; Jia YJ; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1010-3. PubMed ID: 17988579
[TBL] [Abstract][Full Text] [Related]
2. [Establishment of EL4 tumor-bearing mouse models and investigation on immunological mechanisms of anti-tumor effect of melphalan].
Li ML; Li CG; Shu XH; Jia YJ; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Mar; 22(2):235-8. PubMed ID: 16507262
[TBL] [Abstract][Full Text] [Related]
3. [Relationships between tumor shrinkage and peripheral blood cell changes during tumor-rejection induced by a high dose of 5-FU in C57BL/6 mice].
Li CG; Li ML; Shu XH; Liu YJ; Michael N; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Feb; 24(2):156-8. PubMed ID: 18237534
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between TNFalpha and tumor rejection induced by a single dose of melphalan in C57BL/6 mice].
Li ML; Li CG; Shu XH; Jiang MN; Jia YJ; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Apr; 23(4):320-3. PubMed ID: 17428385
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between anti-tumor effects of melphalan and IFN-gamma].
Li ML; Li CG; Shu XH; Jia YJ; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Sep; 22(5):594-6. PubMed ID: 16948903
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between sensitivity of tumor cells to chemotherapeutic agent in vivo and in vitro: experiment with mouse lymphoma cells].
Li CG; Li ML; Shu XH; Jia YJ; Liu YJ; Li M
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(22):1576-8. PubMed ID: 17785116
[TBL] [Abstract][Full Text] [Related]
7. Matching of chemotherapy to mouse strain and lymphoid tumor type to prevent tumor-induced suppression of specific T- and B-cell functions.
Faanes RB; Merluzzi VJ; Williams N; Tarnowski GS; Ralph P
Cancer Res; 1979 Nov; 39(11):4564-74. PubMed ID: 315269
[TBL] [Abstract][Full Text] [Related]
8. [Changes and significance of peripheral blood count in tumor rejection induced by a low dose of melphalan in C57BL/6 mice].
Shu XH; Li CG; Li ML; Michael N; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Jun; 25(6):498-500. PubMed ID: 19500501
[TBL] [Abstract][Full Text] [Related]
9. [Experimental study of interleukin-12 gene vaccines in the treatment of low-load malignant lymphoma (EL4)].
Jiang Q; Da W; Ou Y
Zhonghua Xue Ye Xue Za Zhi; 2001 Nov; 22(11):565-8. PubMed ID: 11855142
[TBL] [Abstract][Full Text] [Related]
10. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma.
Ho RL; Maccubbin DL; Ujházy P; Zaleskis G; Eppolito C; Mihich E; Ehrke MJ
Oncol Res; 1993; 5(9):363-72. PubMed ID: 8038457
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment with n-6 polyunsaturated fatty acids attenuates EL4 thymoma growth and metastasis through enhancing specific and non-specific anti-tumor cytolytic activities and production of TH1 cytokines.
Salem ML
Int Immunopharmacol; 2005 Jun; 5(6):947-60. PubMed ID: 15829411
[TBL] [Abstract][Full Text] [Related]
12. [Changes and significance of peripheral blood platelet count in tumor shrinkage induced by a low dose of CTX in T739 mice].
Li ML; Jia YJ; Jiang MN; Shu XH; Li CG
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Jun; 24(6):567-9. PubMed ID: 18538085
[TBL] [Abstract][Full Text] [Related]
13. Introduction of OX40 ligand into lymphoma cells elicits anti-lymphoma immunity in vivo.
Kaneko H; Hori T; Yanagita S; Kadowaki N; Uchiyama T
Exp Hematol; 2005 Mar; 33(3):336-43. PubMed ID: 15730857
[TBL] [Abstract][Full Text] [Related]
14. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study.
Zaleskis G; Ho RL; Diegelman P; Maccubbin D; Ujházy P; Mihich E; Ehrke MJ
Oncol Res; 1994; 6(4-5):183-94. PubMed ID: 7841541
[TBL] [Abstract][Full Text] [Related]
15. [The significance and function of IFN-gamma on the changes of peripheral blood platelet count during tumor-rejection induced by a low dose of melphalan in C57BL/6 mice].
Li CG; Shu XH; Han D; Li ML; Notter M; Qin ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Nov; 25(11):1016-9. PubMed ID: 19900371
[TBL] [Abstract][Full Text] [Related]
16. Microprocessor-controlled iontophoretic drug delivery of 5-fluorouracil: pharmacodynamic and pharmacokinetic study.
Chandrashekar NS; Shobha Rani RH
J BUON; 2007; 12(4):529-34. PubMed ID: 18067212
[TBL] [Abstract][Full Text] [Related]
17. Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model.
You MH; Kim WJ; Shim W; Lee SR; Lee G; Choi S; Kim DY; Kim YM; Kim H; Han SU
J Gastroenterol Hepatol; 2009 Aug; 24(8):1393-400. PubMed ID: 19486256
[TBL] [Abstract][Full Text] [Related]
18. Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas.
Ho RL; Maccubbin D; Zaleskis G; Krawczyk C; Wing K; Mihich E; Ehrke MJ
Oncol Res; 1993; 5(9):373-81. PubMed ID: 8038458
[TBL] [Abstract][Full Text] [Related]
19. Tumor and tissue distribution of a methotrexate-anti-EL4 immunoglobulin conjugate in EL4 lymphoma-bearing mice.
Uadia P; Blair AH; Ghose T
Cancer Res; 1984 Oct; 44(10):4263-6. PubMed ID: 6467187
[TBL] [Abstract][Full Text] [Related]
20. T cell augments the antitumor activity of tumor-targeting Salmonella.
Lee CH; Hsieh JL; Wu CL; Hsu PY; Shiau AL
Appl Microbiol Biotechnol; 2011 May; 90(4):1381-8. PubMed ID: 21360146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
